Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rizzari, C
Right arrow Articles by Conter, V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rizzari, C
Right arrow Articles by Conter, V
Haematologica, Vol 89, Issue 4, 427-434
Copyright © 2004 by Ferrata Storti Foundation

Journal Article

Outcome of very late relapse in children with acute lymphoblastic leukemia

C Rizzari, MG Valsecchi, M Arico, R Miniero, C Messina, G De Rossi, AM Testi, R Mura, S Galimberti, A Biondi, F Locatelli, and V Conter

Pediatric Department of Monza, Italy. carmelo.rizzari@pediatriamonza.it

BACKGROUND AND OBJECTIVES: Few data are available on the long-term outcome of children who present with a very late relapse of acute lymphoblastic leukemia, so treatment of these patients remains controversial. The present study was aimed at investigating clinical features and treatment outcome of children with very late relapse, diagnosed and treated in Italy in the last 20 years. DESIGN AND METHODS: All children diagnosed in Italian centers with a first relapse of acute lymphoblastic leukemia occurring >or= 60 months after attainment of first complete remission were included in this study. These relapses were diagnosed between 1982 and 1997. RESULTS: Ninety-three patients (58 males, 62.4%) had a first very late relapse occurring at a median time of 6.1 years (range 5.8 - 13.7 years) after the initial diagnosis. At a median follow-up time of 9.1 years after relapse, the overall 5-year survival (SE) and event-free-survival (SE) were 55.6% (5.2) and 39.5% (5.1), respectively. In multivariate analysis the site of relapse was the only significant predictor of duration of the second complete remission. Patients with isolated bone marrow relapse fared worse than those with combined or isolated extramedullary relapse [5-year event-free survival (SE) 24.5% (5.9), 51.3% (11.1) and 68.4% (10.7), respectively; (p=0.004)]. All 7 patients who underwent an allogeneic bone marrow transplantation from a matched related donor are alive in second complete remission. INTERPRETATION AND CONCLUSIONS:In this evaluation patients with a very late relapse isolated to the bone marrow had a poor outcome while re-treatment of extramedullary or combined relapse was associated with better cure rate. Our data suggest that patients with very late isolated bone marrow relapse should be treated intensively; bone marrow transplantation from a matched related donor may be indicated.


This article has been cited by other articles:


Home page
 JCOHome page
M. Arico, M. G. Valsecchi, C. Rizzari, E. Barisone, A. Biondi, F. Casale, F. Locatelli, L. Lo Nigro, M. Luciani, C. Messina, et al.
Long-Term Results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the Prognostic Value of DNA Index in the Framework of Berlin-Frankfurt-Muenster Based Chemotherapy
J. Clin. Oncol., January 10, 2008; 26(2): 283 - 289.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.-H. Pui, D. Pei, J. T. Sandlund, D. Campana, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, S. C. Howard, N. Hijiya, S. Jeha, et al.
Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol., November 1, 2005; 23(31): 7936 - 7941.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.